Dipeptidyl peptidase IV activity and/or structure homologs: Contributing factors in the pathogenesis of rheumatoid arthritis?

Arthritis Research and Therapy

Volumn 7, Issue 6, 2005, Pages 253-269

  Sedo, Aleksi ^a,d   Duke Cohan, Jonathan S ^b   Balaziova, Eva ^a,d   Sedova, Liliana R ^c  

^a CHARLES UNIVERSITY   (Czech Republic)

^b HARVARD MEDICAL SCHOOL   (United States)

^c INSTITUTE OF RHEUMATOLOGY   (Czech Republic)

^d INSTITUTE OF PHYSIOLOGY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ATTRACTIN; BOMBESIN; CALCITONIN GENE RELATED PEPTIDE; CXCL9 CHEMOKINE; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; FOLIC ACID ANTAGONIST; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GASTRIN RELEASING PEPTIDE; GELATINASE; GLUCAGON LIKE PEPTIDE 1; GLUTAMATE CARBOXYPEPTIDASE II; HLA DR ANTIGEN; INTERLEUKIN 1; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1; METHOTREXATE; NEUROPEPTIDE Y; PANCREAS POLYPEPTIDE; PENTOSTATIN; PROLINE DIPEPTIDASE; RANTES; SEPRASE; STROMAL CELL DERIVED FACTOR 1; STROMAL CELL DERIVED FACTOR 1ALPHA; SUBSTANCE P; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANTIINFLAMMATORY ACTIVITY; B LYMPHOCYTE ACTIVATION; CYTOKINE RELEASE; DISEASE SEVERITY; DRUG SPECIFICITY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SPECIFICITY; ENZYME STRUCTURE; HUMAN; IMMUNOPATHOGENESIS; NATURAL KILLER CELL; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; STRUCTURAL HOMOLOGY; SYSTEMIC THERAPY; T LYMPHOCYTE;

ANIMALS; ANTIGENS, CD26; ARTHRITIS, RHEUMATOID; CATALYTIC DOMAIN; HUMANS; ISOENZYMES; MICE; PEPTIDES; PROTEASE INHIBITORS;

EID: 27844453866     PISSN: 14786354     EISSN: None     Source Type: Journal    
DOI: 10.1186/ar1852     Document Type: Review

References (123)

1. Vanhoof G, Goossens F, De Meester I, Hendriks D, Scharpe S: Proline motifs in peptides and their biological processing. Faseb J 1995, 9:736-744.
2. Busek P, Malik R, Sedo A: Dipeptidyl peptidase IV activity and/or structure homologues (DASH) and their substrates in cancer. Int J Biochem Cell Biol 2004, 36:408-421.
3. Mentlein R: Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 1999, 85:9-24.
4. Boonacker E, Van Noorden CJ: The multifunctional or moonlighting protein CD26/DPPIV. Eur J Cell Biol 2003, 82:53-73.
5. Yan S, Marguet D, Dobers J, Reutter W, Fan H: Deficiency of CD26 results in a change of cytokine and immunoglobulin secretion after stimulation by pokeweed mitogen. Eur J Immunol 2003, 33:1519-1527.
6. Cronstein BN, Naime D, Ostad E: The antiinflammatory effects of methotrexate are mediated by adenosine. Adv Exp Med Biol 1994, 370:411-416.
7. Montesinos MC, Desai A, Delano D, Chen JF, Fink JS, Jacobson MA, Cronstein BN: Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68. Arthritis Rheum 2003, 48:240-247.
8. Nakamachi Y, Koshiba M, Nakazawa T, Hatachi S, Saura R, Kurosaka M, Kusaka H, Kumagai S: Specific increase in enzymatic activity of adenosine deaminase 1 in rheumatoid synovial fibroblasts. Arthritis Rheum 2003, 48:668-674.
9. Sedo A, Malik R: Dipeptidyl peptidase IV-like molecules: homologous proteins or homologous activities? Biochim Biophys Acta 2001, 1550:107-116.
10. Duke-Cohan JS, Morimoto C, Rocker JA, Schlossman SF: A novel form of dipeptidylpeptidase IV found in human serum. Isolation, characterization, and comparison with T lymphocyte membrane dipeptidylpeptidase IV (CD26). J Biol Chem 1995, 270:14107-14114.
11. Friedrich D, Kuhn-Wache K, Hoffmann T, Demuth HU: Isolation and characterization of attractin-2. Adv Exp Med Biol 2003, 524:109-113.
12. Proost P, De Meester I, Schols D, Struyf S, Lambeir AM, Wuyts A, Opdenakker G, De Clercq E, Scharpe S, Van Damme J: Aminoterminal truncation of chemokines by CD26/dipeptidyl-peptidase IV. Conversion of RANTES into a potent inhibitor of monocyte chernotaxis and HIV-1-infection. J Biol Chem 1998, 273:7222-7227.
13. Shioda T, Kato H, Ohnishi Y, Tashiro K, Ikegawa M, Nakayama EE, Hu H, Kato A, Sakai Y, Liu H, et al.: Anti-HIV-1 and chemotactic activities of human stromal cell-derived factor 1alpha (SDF-1alpha) and SDF-1beta are abolished by CD26/dipeptidyl peptidase IV-mediated cleavage. Proc Natl Acad Sci USA 1998, 95:6331-6336.
14. Choy EHS, Kingsley GH, Panayi GS: Immunotherapies: T cell, B cell and complement. In Rheumatology. Edited by Hochberg MC, Silman AJ, Smolen J, Weinblatt ME, Weisman MH. 3rd editionn. Edinburgh: Mosby; 2003:449-460.
15. Giannelli G, Erriquez R, lannone F, Marinosci F, Lapadula G, Antonaci S: MMP-2, MMP-9, TIMP-1 and TIMP-2 levels in patients with rheumatoid arthritis and psoriatic arthritis. Clin Exp Rheumatol 2004, 22:335-338.
16. Yan S, Sloane BF: Molecular regulation of human cathepsin B: implication in pathologies. Biol Chem 2003, 384:845-854.
17. Gonzalez-Gronow M, Gawdi G, Pizzo SV: Characterization of the plasminogen receptors of normal and rheumatoid arthritis human synovial fibroblasts. J Biol Chem 1994, 269:4360-4366.
18. Casanova JE, Mishumi Y, Ikehara Y, Hubbard AL, Mostov KE: Direct apical sorting of rat liver dipeptidylpeptidase IV expressed in Madin-Darby canine kidney cells. J Biol Chem 1991, 266:24428-24432.
19. Riemann D, Hansen GH, Niels-Christiansen L, Thorsen E, Immerdal L, Santos AN, Kehlen A, Langner J, Danielsen EM: Caveolae/lipid rafts in fibroblast-like synoviocytes: ectopeptidase-rich membrane microdomains. Biochem J 2001, 354:47-55.
20. Buhling F, Junker U, Reinhold D, Neubert K, Jager L, Ansorge S: Functional role of CD26 on human B lymphocytes. Immunol Lett 1995, 45:47-51.
21. Buhling F, Kunz D, Reinhold D, Ulmer AJ, Ernst M, Flad HD, Ansorge S: Expression and functional role of dipeptidyl peptidase IV (CD26) on human natural killer cells. Nat Immun 1994, 13:270-279.
22. Jackman HL, Tan F, Schraufnagel D, Dragovic T, Dezso B, Becker RP, Erdos EG: Plasma membrane-bound and lysosomal peptidases in human alveolar macrophages. Am J Respir Cell Mol Biol 1995, 13:196-204.
23. Bertotto A, Gerli R, Spinozzi F, Muscat C, Fabietti GM, Crupi S, Castellucci G, De Benedictis FM, De Giorgi G, Britta R, et al.: CD26 surface antigen expression on peripheral blood T lymphocytes from children with Down's syndrome (trisomy 21). Scand J Immunol 1994, 39:633-636.
24. De Meester I, Korom S, Van Damme J, Scharpe S: CD26, let it cut or cut it down. Immunol Today 1999, 20:367-375.
25. Tanaka T, Duke-Cohan JS, Kameoka J, Yaron A, Lee I, Schlossman SF, Morimoto C: Enhancement of antigen-induced T-cell proliferation by soluble CD26/dipeptidyl peptidase IV. Proc Natl Acad Sci USA 1994, 91:3082-3086.
26. Ohnuma K, Munakata Y, Ishii T, Iwata S, Kobayashi S, Hosono O, Kawasaki H, Dang NH, Morimoto C: Soluble CD26/dipeptidyl peptidase IV induces T cell proliferation through CD86 up-regulation on APCs. J Immunol 2001, 167:6745-6755.
27. Ikushima H, Munakata Y, Iwata S, Ohnuma K, Kobayashi S, Dang NH, Morimoto C: Soluble CD26/dipeptidyl peptidase IV enhances transendothelial migration via its interaction with mannose 6-phosphate/insulin-like growth factor II receptor. Cell Immunol 2002, 215:106-110.
28. Kobayashi H, Hosono O, Mimori T, Kawasaki H, Dang NH, Tanaka H, Morimoto C: Reduction of serum soluble CD26/dipeptidyl peptidase IV enzyme activity and its correlation with disease activity in systemic lupus erythematosus. J Rheumatol 2002, 29:1858-1866.
29. Krepela E, Kasafirek E, Vicar J, Kraml J: An essay of dipeptidyl peptidase IV activity in human serum and serum of pregnant women with glycyl-L-proline-1-naphthylamide and other glycyl-L-proline-arylamides as substrates. Physiol Bohemoslov 1983, 32:334-345.
30. Sedo A, Malik R, Votruba M, Hanic T, Hanic O: Serum dipeptidyl peptidase IV activities in Czernobyl zone inhabitants exposed to the power-station catastrophe. Eur J Clin Chem Clin Biochem 1996, 34:447-448.
31. Korum S, De Meester I, Stadlbauer TH, Chandraker A, Schaub M, Sayegh MH, Belyaev A, Haemers A, Scharpe S, Kupiec-Weglinski JW: Inhibition of CD26/dipeptidyl peptidase IV activity in vivo prolongs cardiac allograft survival in rat recipients. Transplantation 1997, 63:1495-1500.
32. Hagihara M, Ohhashi M, Nagatsu T: Activities of dipeptidyl peptidase II and dipeptidyl peptidase IV in mice with lupus erythematosus-like syndrome and in patients with lupus erythematosus and rheumatoid arthritis. Clin Chem 1987, 33: 1463-1465.
33. Cordero OJ, Salgado FJ, Mera-Varela A, Nogueira M: Serum interleukin-12, interleukin-15, soluble CD26, and adenosine deaminase in patients with rheumatoid arthritis. Rheumatol Int 2001, 21:69-74.
34. Kullertz G, Boigk J: Dipeptidyl peptidase IV activity in the serum and synovia of patients with rheumatoid arthritis. Z Rheumatol 1986, 45:52-56.
35. Scholzova E, Sedova L, Mares V, Balaziova E, Vlasicova K, Nytrova P, Sevcik J, Sedo A: Dipeptidyl peptidase IV activity and/or structure homologues (DASH) - the novel players in pathogenesis of rheumatoid and psoriatic arthritides. Eur J Biochem 2004, 271:104-105.
36. Cuchacovich M, Gatica H, Pizzo SV, Gonzalez-Gronow M: Characterization of human serum dipeptidyl peptidase IV (CD26) and analysis of its autoantibodies in patients with rheumatoid arthritis and other aotoimmune diseases. Clin Exp Rheumatol 2001, 19:673-680.
37. Mantle D, Falkous G, Walker D: Quantification of protease activities in synovial fluid from rheumatoid and osteoarthritis cases: comparison with antioxidant and free radical damage markers. Clin Chim Acta 1999, 284:45-58.
38. Cordero OJ, Salgado FJ, Vinuela JE, Nogueira M: Interleukin-12 enhances CD26 expression and dipeptidyl peptidase IV function on human activated lymphocytes. Immunobiology 1997, 197:522-533.
39. Salgado FJ, Vela E, Martin M, Franco R, Nogueira M, Cordero OJ: Mechanisms of CD26/dipeptidyl peptidase IV cytokine-dependent regulation on human activated lymphocytes. Cytokine 2000, 12:1136-1141.
40. Cordero OJ, Salgado FJ, Fernandez-Alonso CM, Herrera C, Lluis C, Franco R, Nogueira M: Cytokines regulate membrane adenosine daminase on human activated lymphocytes. J Leukoc Biol 2001, 70:920-930.
41. Sorrell JM, Brinon L, Baber MA, Caplan AL: Cytokines and glucocorticoids differentially regulate APN/CD13 and DPPIV/CD26 enzyme activities in cultured human dermal fibroblasts. Arch Dermatol Res 2003, 295:160-168.
42. Yamabe T, Takakura K, Sugie K, Kitaoka Y, Takeda S, Okubo Y, Teshigawara K, Yodoi J, Hori T: Induction of the 2B9 antigen/dipeptidyl pepidase IV/CD26 on human natural killer cells by IL-2, IL-12 or IL-15. Immunology 1997, 91:151-158.
43. Brezinschek RI, Lipsky PE, Galea P, Vita R, Oppenheimer-Marks N: Phenotypic characterizaion od CD4+ T cells that exhibit a transendothelial migratory capacity. J Immunol 1995, 154: 3062-3077.
44. Masayuma J, Berman JS, Cruikshank WW, Morimoto C, Center DM: Evidence for recent as well as long term activation of T cells migrating through endothelial cell monolayers in vitro. J Immunol 1992, 148:1367-1374.
45. Ghersi G, Dong H, Goldstein LA, Yeh Y, Hakkinen L, Larjava HS, Chen WT: Regulation of fibroblast migration on collagenous matrix by a cell surface peptidase complex. J Biol Chem 2002, 277:29231-29241.
46. Chen WT, Kelly T: Seprase complexes in cellular invasiveness. Cancer Metastasis Rev 2003, 22:259-269.
47. Mizokami A, Eguchi K, Kawakami A, Ida H, Kawabe Y, Tsukada T, Aoyagi T. Maeda K, Morimoto C, Naataki S: Increased population of high fluorescence 1F7 (CD26) antigen on T cells in synovial fluid of patients with rheumatoid arthritis. J Rheumatol 1996, 23:2022-2026.
48. McInnes IB, Liew FY: Interleukin 15: a proinflammatory role in rheumatoid arthritis synovitis. Immunol Today 1998, 19:75-79.
49. Gerli R, Muscat C, Bertotto A, Bistoni O, Agea E, Tognellini R, Fiorucci G, Cesarotti M, Bombardieri S: CD26 surface molecule involvement in T cell activation and lymphokine synthesis in rheumatoid and other inflammatory synovitis. Clin Immunol Immunopathol 1996, 80:31-37.
50. Duke-Cohan JS, Morimoto C, Rocker JA, Schlossman SF: Serum high molecular weight dipeptidyl peptidase IV (CD26) is similar to a novel antigen DPPT-L released from activaed T cells. J Immunol 1996, 156:1714-1721.
51. Sedova L, Scholzova E, Vlasicova K, Stolfa J, Krystufkova O, Ruzickova S, Sevcik J, Sedo A: Dipeptidyl peptidase IV activity and/or structure homologues (DASH) in blood and synovial fluid mononuclear cells of patients with rheumatoid and psoriatic arthritis. Ann Rheum Dis 2004, 63(Suppl 1):124.
52. Fujita K, Hirano M, Ochiai J, Funabashi M, Nagatsu I, Nagatsu T, Sakakibara S: Serum glycylproline p-nitroanilidase activity in rheumatoid arthritis and systemic lupus erythemaosus. Clin Chim Acta 1978, 88:15-20.
53. Bathon JM, Proud D, Mizutani S, Ward PE: Cultured human synovial fibroblasts rapidly metabolize kinins and neuropeptides. J Clin Invest 1992, 90:981-991.
54. Kamori M, Hagihara M, Nagatsu T, Iwata H, Miura T: Activities of dipeptidyl peptidase II, dipeptidyl peptidase IV, prolyl endopeptidase, and collagenase-like peptidase in synovial membrane from patients with rheumatoid arthritis and osteoarthritis. Biochem Med Metab Biol 1991, 45:154-160.
55. Busso N, Wagtmann N, Herling C, Chobaz-Peclat V, Bischof-Delaloye A, So A, Grouzmann E: Circulating CD26 is negatively associated with inflammation in human and experimental arthritis. Am J Pathol 2005, 166:433-442.
56. Duke-Cohan JS, Tang W, Schlossman SF: Attractin: a cub-family protease involved in T cell-monocyte/macrophage interaction. Adv Exp Med Biol 2000, 477:173-185.
57. Iwaki-Egawa S, Watanabe Y, Matsuno H: Correlations between matrix metalloproteinase-9 and adenosine deaminase isozymes in synovial fluid from paients with rheumatoid arthritis. J Rheumatol 2001, 28:485-489.
58. Kameoka J, Tanaka T, Nojima Y, Schlossman SF, Morimoto C: Direct association of adenosine deaminase with a T cell activation antigen, CD26. Science 1993, 261:466-469.
59. Senten K, Van Der Veken P, De Meester I, Lambeir AM, Scharpe S, Haemers A, Augustyns K: Gamma-amino-substituted analogues of 1-[(S)-2,4-diaminobutanoyl]piperidine as highly potent and selective dipeptidyl peptidase II inhibitors. J Med Chem 2004, 47:2906-2916.
60. Gotoh H, Hagihara M, Nagatsu T, Iwata H, Miura T: Activities of dipeptidyl peptidase II and dipeptidyl peptidase IV in synovial fluid from patients with rheumatoid arthritis and osteoarthritis. Clin Chem 1989, 35:1016-1018.
61. Tang W, Gunn TM, McLaughlin DF, Barsh GS, Schlossman SF, Duke-Cohan JS: Secreted and membrane attractin result from alternative splicing of the human ATRN gene. Proc Natl Acad Sci USA 2000, 97:6025-6030.
62. Liao H, Wu J, Kuhn E, Chin W, Chang B, Jones MD, O'Neil S, Clauser KR, Karl J, Hasler F, et al: Use of mass spectrometry to identify protein biomarkers of disease severity in the synovial fluid and serum of patients with rheumatoid arthritis. Arthritis Rheum 2004, 50:3792-3803.
63. Marguet D, Baggio L, Kobayashi T, Bernard AM, Pierres M, Nielsen PF, Ribel U, Watanabe T, Drucker DJ, Wagtmann N: Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci USA 2000, 97:6874-6879.
64. Gutierrez MA, Garcia ME, Rodriguez JA, Mardonez G, Jacobelli S, Rivero S: Hypothalamic-pituitary-adrenal axis function in patients with active rheumatoid arthritis: a controlled study using insulin hypoglycemia stress test and prolactin stimulation. J Rheumatol 1999, 26:277-281.
65. Masi AT, Bijlsma JW, Chikanza IC, Pitzalis C, Cutolo M: Neuroendocrine, immunologic, and microvascular systems interactions in rheumatoid arthritis: physiopathogenetic and therapeutic perspectives. Semin Arthritis Rheum 1999, 39:65-81.
66. Lord GM, Matarese G, Howard JK, Baker RJ, Bloom SR, Lechler RI: Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature 1998, 394:897-901.
67. Westermark T, Rantapaa-Dahlqvist S, Wallberg-Jonsson S, Kjorell U, Forsgren S: Increased content of bombesin/GRP in human synovial fluid in early arthritis: different pattern compared with substance P. Clin Exp Rheumatol 2001, 19:715-720.
68. Lotz M, Vaughan JH, Carson DA: Effect of neuropeptides on production of inflammatory cytokines by human monocytes. Science 1988, 241:1218-1221.
69. Lambert N, Lescoulie PL, Yassine-Diab B, Enault G, Mazieres B, De Preval C, Cantagrel A: Substance P enhances cytokine-induced vascular cell adhesion molecule-1 (VCAM-1) expression on cultured rheumatoid fibroblast-like synoviocytes. Clin Exp Immunol 1998, 113:269-275.
70. Inoue H, Shimoyama Y, Hirabayashi K, Kajigaya H, Yamamoto S, Oda H, Koshihara Y: Production of neuropeptide substance P by synovial fibroblasts from patients with rheumatoid arthritis and osteoarthritis. Neurosci Lett 2001, 303:149-152.
71. Hernanz A, Medina S, de Miguel E, Martin-Mola E: Effect of calcitonin gene-related peptide, neuropepide Y, substance P, and vasoactive inestinal peptide on interleukin-1beta, interleukin-6 and tumor necrosis factor-alpha production by peripheral whole blood cells from rheumatoid arthritis and osteoarthritis patients. Regul Pept 2003, 115:19-24.
72. Yokoyama MM, Fujimoto K: Role of lymphocyte activation by substance P in rheumatoid arthritis. Int J Tissue React 1990, 12:1-9.
73. Covas MJ, Pinto LA, Pereira Da Silva JA, Victorino RM: Effects of the neuropeptide, substance P, on lymphocyte proliferation in rheumatoid arthritis. J Int Med Res 1995, 23:431-438.
74. Covas MJ, Pinto LA, Victorino RM: Effects of substance P on human T cell function and the modulatory role of peptidase inhibitors. Int J Clin Lab Res 1997, 27:129-134.
75. Zukowska Z, Pons J, Lee EW, Li L: Neuropeptide Y: a new mediator linking sympathetic nerves, blood vessels and immune system? Can J Physiol Pharmacol 2003, 81:89-94.
76. Schwarz H, Villiger PM, von Kempis J, Lotz M: Neuropeptide Y is an inducible gene in the human immune system. J Neuroimmunol 1994, 51:53-61.
77. Silva AP, Cavadas C, Baisse-Agushi B, Spertini O, Brunner HR, Grouzmann E: NPY, NPY receptors, and DPP IV activity are modulated by LPS, TNF-alpha and IFN-gamma in HUVEC. Regul Pept 2003, 116:71-79.
78. Straub RH, Mayer M, Kreutz M. Leeb S, Scholmerich J, Falk W: Neurotransmitters of the sympathetic nerve terminal are powerful chemoattractants for monocytes. J Leukoc Biol 2000, 67: 553-558.
79. Appelgren A, Appelgren B, Eriksson S, Kopp S, Lundeberg T, Nylander M, Theodorsson E: Neuropeptides in temporomandibular joints wih rheumatoid arthritis: a clinical study. Scand J Dent Res 1991, 99:519-521.
80. Dimitrijevic M, Stanojevic S, Vujic V, Kovacevic-Jovanovic V, Beck-Sickinger A, Demuth H, von Horsten S: Effect of neuropeptide Y on inflammatory paw edema in the rat: involvement of peripheral NPY Y1 and Y5 receptors and interaction with dipeptidyl-peptidase IV (CD26). J Neuroimmunol 2002, 129:35-42.
81. Arnalich F, de Miguel E, Perez-Ayala C, Martinez M, Vazquez JJ, Gijon-Banos J, Hernanz A: Neuropeptides and interleukin-6 in human joint inflammation relationship between inraarticular substance P and interleukin-6 concentrations. Neurosci Lett 1994, 170:251-254.
82. Wang F, Millet I, Bottomly K, Vignery A: Calcitonin gene-related peptide inhibits interleukin 2 production by murine T lumphocytes. J Biol Chem 1992, 267:21052-21057.
83. Juarranz MG, Santiago B, Torroba M, Gutierrez-Canas I, Palao G, Galindo M, Abad C, Martinez C, Leceta J, Pablos JL, et al: Vasoactive intestinal peptide modulates proinflammatory mediator synthesis in osteoarthritic and rheumatoid synovial cells. Rheumatology (Oxford) 2004, 43:416-422.
84. Delgado M, Abad C, Martinez C, Leceta J, Gomariz RP: Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat Med 2001, 7:563-568.
85. Del Rio M, De la Fuente M: Stimulaion of natural killer (NK) and antibody-dependent cellular cytotoxicity (ADCC) activities in murine leukocytes by bombesin-related peptides requires the presence of adherent cells. Regul Pept 1995, 60:159-166.
86. Hill DJ, McDonald TJ: Mitogenic action of gastrin-releasing polypeptide on isolated epiphyseal growth plate chondrocytes from the ovine fetus. Endocrinology 1992, 130:2811-2819.
87. Bertazzolo N, Punzil L, Stefani MP, Cesaro G, Pianon M, Finco B, Todesco S: Interrelationships between interleukin (IL)-1, IL-6 and IL-8 in synovial fluid of various arthropathies. Agents Actions 1994, 41:90-92.
88. Partsch G, Wagner E, Leeb BF, Broll H, Dunky a, Smolen JS: T cell derived cytokines in psoriatic arthritis synovial fluids. Ann Rheum Dis 1998, 57:691-693.
89. Ritchin C, Haas-Smith SA, Hicks D, Cappuccio J, Osterland CK, Looney RJ: Patterns of cytokine production in psoriatic synovium. J Rheumatol 1998, 25:1544-1552.
90. Steiner G, Tohidast-Akrad M, Witzmann G, Vesely M, Studnicka-Benke A, Gal A, Kunaver M, Zenz P, Smolen JS: Cytokine production by synovial T cells in rheumatoid arthritis. Rheumatology (Oxford) 1999, 38:202-213.
91. Hoffmann T, Faust J, Neubert K, Ansorge S: Dipeptidyl peptidase IV (CD 26) and aminopeptidase N (CD 13) catalyzed hydrolysis of cytokines and peptides with N-ternimal cytokine sequences. FEBS Lett 1993, 336:61-64.
92. Bauvois B, Sanceau J, Wietzerbin J: Human U937 cell surface peptidase activities: characterization and degradative effect on tumor necrosis factor-alpha. Eur J Immunol 1992, 22:923-930.
93. Firestein GS: The T cell cometh: interplay between adaptive immunity and cytokine networks in rheumatoid arthritis. J Clin Invest 2004, 114:471-474.
94. Konig A, Krenn V, Toksoy a, Gerhard N, Gillitzer R: Mig, GRO alpha and RANTES messenger RNA expression in lining layer, infiltrates and different leucocyte populations of synovial tissue from patients with rheumatoid arthritis, psoriatic arthritis and osteoarthritis. Virchows Arch 2000, 436:449-458.
95. Loetscher P, Moser B: Homing chemokines in rheumatoid arthritis. Arthritis Res 2002, 4:233-236.
96. Robinson E, Keystone EC, Schall TJ, Gillett N, Fish EN: Chemokine expression in rheumatoid arthritis (RA): evidence of RANTES and macrophage inflammatory protein (MIP)-1 beta production by synovial T cells. Clin Exp Immunol 1995, 101:398-407.
97. Wang CR, Liu MF: Regulation of CCR5 expression and MIP-1alpha production in CD4+T cells from paients with rheumatoid arthritis. Clin Exp Immunol 2003, 132:371-378.
98. Guan E, Wang J, Norcross MA: Amino-terminal processing of MIP-1beta/CCL4 by CD26/dipeptidyl-peptidase IV. J Cell Biochem 2004, 92:53-64.
99. Katschke KJ Jr, Rottman JB, Ruth JH, Qin S, Wu L, LaRosa G, Ponath P, Park CC, Pope RM, Koch AE: Differential expression of chemokine receptors on peripheral blood, synovial fluid, and synovial tissue monocytes/macrophages in rheumatoid arthritis. Arthritis Rheum 2001, 44:1022-1032.
100. Lambeir AM, Durinx C, Scharpe S, De Meester I: Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 2003, 40:209-294.
101. Proost P, Schutyser E, Menten P, Struyf S, Wuyts A, Opdenakker G, Detheux M, Parmentier M, Druinx C, Lambeir AM, et al.: Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties. Blood 2001, 98:3554-3561.
102. Hanaoka R, Kasama T, Muramatsu M, Yajima N, Shiozawa F, Miwa Y, Negishi M, Ide H, Miyaoka H, Uchida H, et al.: A novel mechanism for the regulation of IFN-gamma inducible protein-10 expression in rheumatoid arthritis. Arthritis Res Ther 2003, 5: R74-81.
103. Patel DD, Zachariah JP, Whichard LP: CXCR3 and CCR5 ligands in rheumatoid arthritis synovium. Clin Immunol 2001, 98:39-45.
104. Bradfield PF, Amft N, Vernon-Wilson E, Exley AE, Parsonage G, Rainger GE, Nash GB, Thomas AM, Simmons DL, Salmon M, et al.: Rheumatoid fibroblast-like synoviocytes overexpress the chemokine stromal cell-derived factor 1 (CXCL12), which supports cistinct patterns and rates of CD4+ and CD8+ T cell migration within synovial tissue. Arthritis Rheum 2003, 48: 2472-2482.
105. Buckley CD, Amft N, Bradfield PF, Pilling D, Ross E, Arenzana-Seis-dedos F, Amara A, Curnow SJ, Lord JM, Scheel-Toellner D, et al.: Persistent inductiion of the chemokine receptor CXCR4 by TGF-beta 1 on synovial T cells contributes to their accumulation within he rheumatoid synovium. J Immunol 2000, 165:3423-3429.
106. Herrera C, Morimoto C, Blanco J, Mallol J, Arenzana F, Lluis C, Franco R: Comodulation of CXCR4 and CD26 in human lymphocytes. J Biol Chem 2001, 276:19532-19539.
107. Yang YF, Mukai T, Gao P, Yamaguchi N, Ono S, Iwaki H, Obika S, Imanishi T, Tsujimura T, Hamaoka T, et al.: A non-peptide CCR5 antagonist inhibits collagen-induced arthritis by modulaion T cell migration without affecting anti-collagen T cell responses. Eur J Immunol 2002, 32:2124-2132.
108. Iwata S, Yamaguchi N, Munakata Y, Ikushima H, Lee JF, Hosono O, Schlossman SF, Morimoto C: CD26/dipeptidyl peptidase IV differentially regulates the chemotaxis of T cells and monocytes toward RANTES: possible mechanism for the switch from innate to acquired immune response. Int Immunol 1999, 11:417-426.
109. Wiedeman PE, Trevillyan JM: Dipeptidyl peptidase IV inhibitors for the treatment of impaired glucose tolerance and type 2 diabetes. Curr Opin Investig Drugs 2003, 4:412-420.
110. Steinbrecher A, Reinhold D, Quigley L, Gado A, Tresser N, Izikson L, Born I, Faust J, Neubert K, Martin R, et al.: Targeting dipeptidyl peptidase IV (CD26) suppresses autoimmune encephalomyelitis and up-regulates TGF-beta 1 secretion in vivo. J Immunol 2001, 166:2041-2048.
111. Korom S, De Meester I, Schmidbauer G, Pratschke J, Brendel MD, Durinx C, Schwemmle K, Haemers A, Scharpe S, Kupiec-Weglinski JW: Specific inhibition of CD26/DPP IV enzymatic activity in allograft recipients: effects on humoral immunity. Transplant Proc 1999, 31:778.
112. Reinhold D, Hemmer B, Gran B, Steinbrecher A, Brocke S, Kahne T, Wrenger S, Born I, Faust J, Neubert K, et al: Dipeptidyl peptidase IV (CD26): role in T cell activation and autolmmune disease. Adv Exp Med Biol 2000,477:155-160.
113. Reinhold D, Bank U, Buhling F, Kahne T, Kunt D, Faust J, Neubert K, Ansorge S: Inhibitors of dipeptidyl peptidase IV (DP IV, CD26) specifically suppress proliferation and modulate cytokine production of strongly CD26 expressing U937 cells. Immunobiology 1994, 192:121-136.
114. Tanaka S, Murakami T, Horikawa H, Sugiura M, Kawashima K, Sugita T: Suppression of arthritis by the inhibitors of dipeptidyl peptidase IV. Int J lmmunopharmacol 1997, 19:15-24.
115. Tanaka S, Murakami T, Nonaka N, Ohnuki T, Yamada M, Sugita T: Anti-arthritic effects of the novel dipeptidyl peptidase IV inhibitors TMC-2A and TSL-225. Immunopharmacology 1998, 40:21-26.
116. Williams YN, Baba H, Hayashi S, Ikai H, Sugita T, Tanaka S, Miyasaka N, Kubota T: Dipeptidyl peptidase IV on activated T cells as a target molecule for therapy of rheumatoid arthritis. Clin Exp Immunol 2003, 131:68-74.
117. Williams YN, Sugita T, Nosaka Y, Kubota T: Suppression of fibroblast activity by an inhibitor of dipeptidyl peptidase IV: a possible therapeutic strategy for rheumatoid arthritis. Clin Exp Rheumatol 2003, 21:685.
118. Calvo CF, Chavanel G, Senik A: Substance P enhances IL-2 expression in activated human T cells. J Immunol 1992, 148: 3498-3504.
119. Laurenzi MA, Persson MA, Dalsgaard CJ, Ringden 0: Stimulation of human B lymphocyte differentiation by the neuropeptides substance P and neurokinin A. Scand J Immunol 1989, 30:695-701.
120. Proudfoot AE, Handel TM, Johnson Z, Lau EK, LiWang P, Clark-Lewis I, Borlat F, Wells TN, Kosco-Vilbois MH: Glycosarninoglycan binding and oligomerizabon are essential for the in vivo activity of certain chemokines. Proc Natl Acad Sci USA 2003, 100:1885-1890.
121. Wollheim FA: Predictors of joint damage in rheumatoid arthritis. Apmis 1996, 104:81-93.
122. Nestorov I: Clinical pharmacokinetics of tumor necrosis factor antagonists. J Rheumatol Suppl 2005, 74:13-18.
123. Muscat C, Bertotto A, Agea E, Bistoni O, Ercolani R, Tognellini R, Spinozzi F, Cesarotti M, Gerli R: Expression and functional role of 1F7 (CD26) antigen on peripheral blood and synovial fluid T cells in rheumatoid arthritis patients. Clin Exp Immunol 1994, 98:252-256.